Showing results (91-100 of 112) with videos related to
Sort By:
Pageof 12
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.Nature Communications|June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.JTO Clinical and Research Reports|April 27, 2026
Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARDByoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARDSarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell InfiltrationJay M Lee, Mi-Heon Lee, Edward Garon, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.The New England Journal of Medicine|October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 InsertionsCaicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.Journal for Immunotherapy of Cancer|February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.Pageof 12